Langerhans Cell Histiocytosis: A Clinicopathologic Review and Molecular Pathogenetic Update.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26414464.
- Also identified by DOI 10.5858/arpa.2015-0199-RA.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Langerhans cell histiocytosis (LCH) comprises a wide spectrum of clinical disorders that have in common a proliferation of Langerhans-type cells with characteristic morphologic, immunophenotypic, and ultrastructural features. In part because of the diverse clinical manifestations of LCH, there has long been controversy over whether LCH is best considered a reactive process or a neoplasm. Herein, we discuss the clinical and pathologic features of LCH, including recent advances in the understanding of the molecular pathogenesis of this disease that support its categorization as a neoplasm. We also review the implications that these recently described molecular characteristics may have on risk stratification and treatment of LCH.
Medical subject headings
- Histiocytosis, Langerhans-Cell
- Langerhans Cells